UK biotech Myricx Bio has tapped into the red-hot interest among investors for companies working on antibody-drug conjugates (ADCs) for cancer, raising £90 million ($115 million) in a first
Potentially adding to a lengthening list of positive health benefits of GLP-1 agonist drugs, a new study has suggested they may also reduce the risk of a bevy of cancers associated with bei
Kicking off in Chicago on the 31st May, the 2024 American Society of Clinical Oncology’s Annual Meeting - known as ASCO - welcomed more than forty thousand healthcare professionals through
Artificial intelligence software developed by Pangea Biomed can predict the chances that a patient will respond to cancer treatment by looking at tumour histopathology images.